Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report

INTRODUCTION: In the past, no effective systemic therapy has existed for patients with advanced hepatocellular carcinoma. Sorafenib, an oral multikinase inhibitor, has recently been shown to improve overall survival in patients with advanced hepatocellular carcinoma in two randomized, double-blinded...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuwaki, Yusuke, Nakazawa, Takahide, Hidaka, Hisashi, Shibuya, Akitaka, Koizumi, Wasaburo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275456/
https://www.ncbi.nlm.nih.gov/pubmed/22280970
http://dx.doi.org/10.1186/1752-1947-6-38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275456/
https://www.ncbi.nlm.nih.gov/pubmed/22280970
http://dx.doi.org/10.1186/1752-1947-6-38

Ejemplares similares